Epizyme® is a clinical stage biopharmaceutical company that is creating novel epigenetic therapies for cancer patients. Based on the belief that dysregulation of epigenetic activity plays a critical role in cancer and many other diseases, we have built a discovery platform that we use to create small molecule inhibitors of chromatin remodeling enzymes.
When Epizyme was founded in 2007, we recognized that the histone methyltransferases, or HMT, class of epigenetic enzymes might contain many potential oncogenes and presented the opportunity to discover, develop and commercialize multiple cancer therapeutics. We have focused our proprietary platform to create small molecule inhibitors of this 96-member class of enzymes.
To date we have built a proprietary library of more than 30,000 HMT inhibitors; we have advanced multiple pipeline targets and have clinical programs targeting the HMTs EZH2 (for certain subtypes of Non-Hodgkin Lymphoma and genetically-defined solid tumors including malignant rhabdoid tumors and other INI1-deficient and SMARCA4-negative tumors) and DOT1L (for the treatment of pediatric acute leukemias with genetic alterations of MLL).